Switch to infliximab subcutaneous during SARS-CoV-2 pandemic: preliminary results

MLA

Paula Fernández Álvarez, et al. “Switch to Infliximab Subcutaneous during SARS-CoV-2 Pandemic: Preliminary Results.” Revista Española de Enfermedades Digestivas, Jan. 2021. EBSCOhost, https://doi.org/10.17235/reed.2021.8320/2021.

APA

Paula Fernández Álvarez, Federico Argüelles-Arias, Ángel Caunedo Álvarez, María Belén Maldonado Pérez, Luisa Castro Laria, Vicente Merino-Bohórquez, María Belvis Jiménez, & Miguel Ángel Calleja Hernández. (2021). Switch to infliximab subcutaneous during SARS-CoV-2 pandemic: preliminary results. Revista Española de Enfermedades Digestivas. https://doi.org/10.17235/reed.2021.8320/2021

Chicago

Paula Fernández Álvarez, Federico Argüelles-Arias, Ángel Caunedo Álvarez, María Belén Maldonado Pérez, Luisa Castro Laria, Vicente Merino-Bohórquez, María Belvis Jiménez, and Miguel Ángel Calleja Hernández. 2021. “Switch to Infliximab Subcutaneous during SARS-CoV-2 Pandemic: Preliminary Results.” Revista Española de Enfermedades Digestivas, January. doi:10.17235/reed.2021.8320/2021.